Next-Gen Sequencing: Hot as a Research Tool; Not for Qiagen's Companion Dx Strategy
July 20, 2011
Next-Gen Sequencing: Hot as a Research Tool; Not for Qiagen's Companion Dx Strategy
Advanced sequencing technologies are great for discovery, but not ready to be incorporated into Qiagen's commercial companion diagnostics portfolio, according to CEO Peer Schatz.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Diaceutics Report Sheds Doubt on Pharmas' Personalized Medicine Preparedness
June 15, 2011 / Pharmacogenomics Reporter - With New Hires to Pharma Business Development Team, Qiagen Prioritizes Rx/Dx Partnership Strategy
April 21, 2010 / Pharmacogenomics Reporter - With Medco Around for Dx Shops Developing PGx Tests Independently, Who Needs Pharma?
April 14, 2010 / Pharmacogenomics Reporter - Asuragen Launches Cancer Panels Optimized for FFPE Tissue; Plans to Sell Proprietary Reagents
April 10, 2013 / Clinical Sequencing News - Personalized Medicine in 2012: Industry Takes a Wait-and-See Approach Due to Market Unknowns
January 9, 2013 / Pharmacogenomics Reporter